CDE Detailed Report | NINDS Common Data Elements

Disease: NeuroRehab
Subdomain Name: Disease-Specific Health-Related Quality of Life
CRF: Parkinson's Disease Quality of Life Scale (PDQUALIF)

Displaying 1 - 33 of 33

CDE ID	CDE Name	Variable Name	Definition	Short Description	Question Text	Permissible Values	Description	Data Type	Disease Specific Instructions	Disease Specific Reference	Population	Classification (e.g., Core)	Version Number	Version Date	CRF Name (CRF Module / Guidance)	Subdomain Name	Domain Name	Input Restrictions
C17365	Parkinson's Disease Quality of Life (PDQUALIF) - night wakeup bathroom scale	PDQUALIFNghtWakeBRScale	Rating scale for waking up at night due to the need to go to the bathroom as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for waking up at night due to the need to go to the bathroom as part of Parkinson's Disease Quality of Life (PDQUALIF) form	The need to go to the bathroom wakes me in the night	Never;Rarely;Sometimes;Frequently;Always	Never;Rarely;Sometimes;Frequently;Always	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17376	Parkinson's Disease Quality of Life (PDQUALIF) - difficulty ask help scale	PDQUALIFAskHelpScale	Rating scale for feeling difficult to ask others for help as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for feeling difficult to ask others for help as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Asking others for help is difficult for me	Never;Rarely;Sometimes;Frequently;Always	Never;Rarely;Sometimes;Frequently;Always	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17387	Parkinson's Disease Quality of Life (PDQUALIF) - writing speaking problem 7 days scale	PDQUALIFWrtSpkProb7DScale	Rating scale for a problem in written or spoken communication in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for a problem in written or spoken communication in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form	In the past 7 days, written or spoken communication is a problem for me	Never;Rarely;Sometimes;Frequently;Always	Never;Rarely;Sometimes;Frequently;Always	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17366	Parkinson's Disease Quality of Life (PDQUALIF) - affection ability scale	PDQUALIFAffectnAbScale	Rating scale for ability to show affection in intimate or sexual ways affected by the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for ability to show affection in intimate or sexual ways affected by the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form	My Parkinson's symptoms affect my ability to show affection in intimate or sexual ways	Never;Rarely;Sometimes;Frequently;Always	Never;Rarely;Sometimes;Frequently;Always	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17377	Parkinson's Disease Quality of Life (PDQUALIF) - independent important scale	PDQUALIFIndepImportScale	Rating scale for feeling important to maintain independence as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for feeling important to maintain independence as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Maintaining my independence is important to me	Never;Rarely;Sometimes;Frequently;Always	Never;Rarely;Sometimes;Frequently;Always	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17388	Parkinson's Disease Quality of Life (PDQUALIF) - fatigue participation problem 7 days scale	PDQUALIFFatigPartProb7DScale	Rating scale for problem in participation in activities, household chores, shopping or yard work due to fatigue in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for problem in participation in activities, household chores, shopping or yard work due to fatigue in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form	In the past 7 days, fatigue makes participation in activities, household chores, shopping or yard work a problem for me	Always;Frequently;Sometimes;Rarely;Never	Always;Frequently;Sometimes;Rarely;Never	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17367	Parkinson's Disease Quality of Life (PDQUALIF) - aching limb scale	PDQUALIFAcheLimbScale	Rating Scale for having aching/burning/coldness/numbness in the hand/feet as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating Scale for having aching/burning/coldness/numbness in the hand/feet as part of Parkinson's Disease Quality of Life (PDQUALIF) form	I have aching/burning/coldness/numbness in my hand/feet	Never;Rarely;Sometimes;Frequently;Always	Never;Rarely;Sometimes;Frequently;Always	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17378	Parkinson's Disease Quality of Life (PDQUALIF) - difficulty adjust change scale	PDQUALIFDiffcltAdjtChngScale	Rating scale for feeling difficult to adjust to the changes which have taken place in the body as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for feeling difficult to adjust to the changes which have taken place in the body as part of Parkinson's Disease Quality of Life (PDQUALIF) form	It has been difficult to adjust to the changes which have taken place in my body	Very;Moderately;Somewhat;Slightly;Not at all	Very;Moderately;Somewhat;Slightly;Not at all	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17389	Parkinson's Disease Quality of Life (PDQUALIF) - usual share interfered 7 days scale	PDQUALIFUsuSharInterf7DScale	Rating scale for the ability to do usual share in the home interfered by the Parkinson's symptoms in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for the ability to do usual share in the home interfered by the Parkinson's symptoms in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form	In the past 7 days, my Parkinson's symptoms interfere with my ability to do my usual share in the home	Always;Frequently;Sometimes;Rarely;Never	Always;Frequently;Sometimes;Rarely;Never	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17368	Parkinson's Disease Quality of Life (PDQUALIF) - difficulty bladder control scale	PDQUALIFDiffcltBladContScale	Rating scale for difficulty with bladder control (frequency, urgency, inability) as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for difficulty with bladder control (frequency, urgency, inability) as part of Parkinson's Disease Quality of Life (PDQUALIF) form	I have difficulty with bladder control (frequency, urgency, inability)	Never;Rarely;Sometimes;Frequently;Always	Never;Rarely;Sometimes;Frequently;Always	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17379	Parkinson's Disease Quality of Life (PDQUALIF) - social life not affected scale	PDQUALIFSocLfNotAffctedScale	Rating scale for feeling that the social life has not been affected by the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for feeling that the social life has not been affected by the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form	My Parkinson's symptoms have not affected my social life	Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree	Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17390	Parkinson's Disease Quality of Life (PDQUALIF) - not sleep with spouse night 7 days scale	PDQUALIFNotSlpNghtWSpous7DScl	Rating scale for keeping you from sleeping with the spouse/partner due to the nighttime symptoms in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for keeping you from sleeping with the spouse/partner due to the nighttime symptoms in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form	In the past 7 days, my nighttime symptoms keep me from sleeping with my spouse/partner	Everyday;5-6 Days;3-4 Days;1-2 days;Never	Everyday;5-6 Days;3-4 Days;1-2 days;Never	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17369	Parkinson's Disease Quality of Life (PDQUALIF) - constipation scale	PDQUALIFConstipScale	Rating scale for constipation problem as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for constipation problem as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Constipation is a problem	Never;Rarely;Sometimes;Frequently;Always	Never;Rarely;Sometimes;Frequently;Always	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17380	Parkinson's Disease Quality of Life (PDQUALIF) - travel important scale	PDQUALIFTravelImportScale	Rating scale for feeling that travel remains an important part of leisure activities as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for feeling that travel remains an important part of leisure activities as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Travel remains an important part of my leisure activities	Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree	Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17391	Parkinson's Disease Quality of Life (PDQUALIF) - driving interfered 7 days scale	PDQUALIFDrivInterf7DScale	Rating scale for interfered driving ability due to Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for interfered driving ability due to Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form	In the past 7 days, my Parkinson's symptoms have interfered with my driving ability	Doesn't Apply;Rarely;Sometimes;Frequently;Constantly	Doesn't Apply;Rarely;Sometimes;Frequently;Constantly	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17370	Parkinson's Disease Quality of Life (PDQUALIF) - trouble fall asleep scale	PDQUALIFTroubFallAslpScale	Rating scale for trouble falling asleep, or waking early due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for trouble falling asleep, or waking early due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form	My Parkinson's symptoms cause me to have trouble falling asleep, or waking early	Never;Rarely;Sometimes;Frequently;Always	Never;Rarely;Sometimes;Frequently;Always	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17381	Parkinson's Disease Quality of Life (PDQUALIF) - family role affected scale	PDQUALIFFamRoleAffctedScale	Rating scale for family role and relationship affected by the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for family role and relationship affected by the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form	My Parkinson's symptoms have affected my family role and relationship	Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree	Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17392	Parkinson's Disease Quality of Life (PDQUALIF) - financial strain 7 days scale	PDQUALIFFinancStrain7DaysScale	Rating scale for a financial strain due to the illness in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for a financial strain due to the illness in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form	In the past 7 days, my illness has caused a financial strain for me and my family	Doesn't Apply;Rarely a concern;Sometimes;Frequently;Constantly	Doesn't Apply;Rarely a concern;Sometimes;Frequently;Constantly	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17371	Parkinson's Disease Quality of Life (PDQUALIF) - trouble stay asleep scale	PDQUALIFTroubStayAslpScale	Rating scale for trouble staying asleep as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for trouble staying asleep as part of Parkinson's Disease Quality of Life (PDQUALIF) form	I have trouble staying asleep	Never;Rarely;Sometimes;Frequently;Always	Never;Rarely;Sometimes;Frequently;Always	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17382	Parkinson's Disease Quality of Life (PDQUALIF) - away from social scale	PDQUALIFAwyFrmSocScale	Rating scale for staying away from social gatherings due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for staying away from social gatherings due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form	My Parkinson's symptoms cause me to stay away from social gatherings	Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree	Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17361	Parkinson's Disease Quality of Life (PDQUALIF) - lightheaded scale	PDQUALIFLghtHdScale	Rating scale for lightheaded symptom caused by changing positions (lying to standing, or sitting to standing) as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for lightheaded symptom caused by changing positions (lying to standing, or sitting to standing) as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Changing positions causes me to become lightheaded (lying to standing, or sitting to standing)	Never;Rarely;Sometimes;Occasionally;Always	Never;Rarely;Sometimes;Occasionally;Always	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17393	Parkinson's Disease Quality of Life (PDQUALIF) - symptoms 7days compare 6-months scale	PDQUALIFSymp7DComp6MScale	Rating scale for the Parkinson's symptoms in past 7 days compared to 6 months ago as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for the Parkinson's symptoms in past 7 days compared to 6 months ago as part of Parkinson's Disease Quality of Life (PDQUALIF) form	In the past 7 days compared to 6 months ago, my Parkinson's symptoms are	Much better;Somewhat better;About the same;Somewhat worse;Much Worse	Much better;Somewhat better;About the same;Somewhat worse;Much Worse	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17372	Parkinson's Disease Quality of Life (PDQUALIF) - positive outlook scale	PDQUALIFPositvOutlkScale	Rating scale for maintaining a positive outlook due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for maintaining a positive outlook due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form	My Parkinson's symptoms make it hard to maintain a positive outlook	Never;Rarely;Sometimes;Frequently;Always	Never;Rarely;Sometimes;Frequently;Always	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17383	Parkinson's Disease Quality of Life (PDQUALIF) - family friends view change scale	PDQUALIFFamFridViewChngScale	Rating scale for feeing that your spouse/children/friends' view of you has changed because of your illness as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for feeing that your spouse/children/friends' view of you has changed because of your illness as part of Parkinson's Disease Quality of Life (PDQUALIF) form	My spouse/children/friends' view of me has changed because of my illness	Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree	Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17362	Parkinson's Disease Quality of Life (PDQUALIF) - trouble balance scale	PDQUALIFTroubBalScale	Rating scale for trouble keeping balance while walking as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for trouble keeping balance while walking as part of Parkinson's Disease Quality of Life (PDQUALIF) form	When walking, I have trouble keeping my balance	Never;Rarely;Sometimes;Occasionally;Always	Never;Rarely;Sometimes;Occasionally;Always	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17373	Parkinson's Disease Quality of Life (PDQUALIF) - feel burden scale	PDQUALIFFeelBurdScale	Rating scale for feeling a burden to other people due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for feeling a burden to other people due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form	My Parkinson's symptoms cause me to feel like a burden to other people	Never;Rarely;Sometimes;Frequently;Always	Never;Rarely;Sometimes;Frequently;Always	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17384	Parkinson's Disease Quality of Life (PDQUALIF) - less sexually desirable scale	PDQUALIFLesSexDesirblScale	Rating scale for feeling of less sexually desirable because of the illness as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for feeling of less sexually desirable because of the illness as part of Parkinson's Disease Quality of Life (PDQUALIF) form	I feel I am less sexually desirable because of my illness	Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree	Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17363	Parkinson's Disease Quality of Life (PDQUALIF) - difficult swallowing scale	PDQUALIFDiffcltSwallScale	Rating scale for difficulty swallowing while eating or drinking liquids as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for difficulty swallowing while eating or drinking liquids as part of Parkinson's Disease Quality of Life (PDQUALIF) form	When eating or drinking liquids, I have difficulty swallowing	Never;Rarely;Sometimes;Frequently;Always	Never;Rarely;Sometimes;Frequently;Always	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17374	Parkinson's Disease Quality of Life (PDQUALIF) - affected social life scale	PDQUALIFSocLfAffctedScale	Rating scale for affected social life by Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for affected social life by Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form	My Parkinson's symptoms have affected my social life	Never;Rarely;Sometimes;Frequently;Always	Never;Rarely;Sometimes;Frequently;Always	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17385	Parkinson's Disease Quality of Life (PDQUALIF) - hygiene independence 7 days scale	PDQUALIFHygienIndep7DaysScale	Rating scale for personal hygiene (bathing, hair care, make up, shaving, or toileting) independence in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for personal hygiene (bathing, hair care, make up, shaving, or toileting) independence in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form	In the past 7 days, in my personal hygiene (bathing, hair care, make up, shaving, or toileting) I have been independent	Everyday;5-6 Days;3-4 Days;1-2 days;Never	Everyday;5-6 Days;3-4 Days;1-2 days;Never	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17364	Parkinson's Disease Quality of Life (PDQUALIF) - communication ability scale	PDQUALIFCommunAbScale	Rating scale for ability of communication with people affected by illness as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for ability of communication with people affected by illness as part of Parkinson's Disease Quality of Life (PDQUALIF) form	My Parkinson's symptoms affect my ability to communicate with people	Never;Rarely;Sometimes;Frequently;Always	Never;Rarely;Sometimes;Frequently;Always	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17375	Parkinson's Disease Quality of Life (PDQUALIF) - worry future scale	PDQUALIFWorryFutScale	Rating scale for worrying about what the future has in store as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for worrying about what the future has in store as part of Parkinson's Disease Quality of Life (PDQUALIF) form	I worry about what the future has in store	Never;Rarely;Sometimes;Frequently;Always	Never;Rarely;Sometimes;Frequently;Always	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected
C17386	Parkinson's Disease Quality of Life (PDQUALIF) - food preparation eating independent 7 days scale	PDQUALIFFoodPrepEatIndep7DScl	Rating scale for preparing and eating independently in the past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form	Rating scale for preparing and eating independently in the past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form	In the past 7 days, in food preparation or eating I am independent	Everyday;5-6 Days;3-4 Days;1-2 days;Never	Everyday;5-6 Days;3-4 Days;1-2 days;Never	Alphanumeric	Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.	PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.	Adult	NeuroRehab Supplemental-Highly Recommended	3.00	2013-07-18 09:11:50.26	Parkinson's Disease Quality of Life Scale (PDQUALIF)	Disease-Specific Health-Related Quality of Life	Outcomes and End Points	Single Pre-Defined Value Selected